Medtronic (MDT) announces one-year results from its first randomized clinical trial investigating renal denervation showing patients who initially received treatment with the Symplicity renal denervation system sustained a significant drop in blood pressure compared to baseline at 12 months, plus no device-related serious adverse events, no late vascular complications, and no significant decline in kidney function.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Thu, 2:30PM)
at Zacks.com (Feb 26, 2015)
at Zacks.com (Feb 24, 2015)
UPDATE: Medtronic plc: FDA Approves the VenaSeal Closure System for Treatment of Clinically Symptomatic Venous Refluxat Benzinga.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs